• Fund: EUREKA! FUND I
  • Sector: HEALTH TECH
  • Technology: MAGNETIC BALLOON TECHNOLOGY FOR COLONOSCOPY
  • First Investment: APRIL 2021
  • Round: SERIES B, 8.2 M €
  • Co-investors: A11-VENTURE, PANAKES PARTNERS SGR, ESTOR, HTH, PROGRESS TECH TRANSFER, LIFTT, KAIROS PARTNERS SGR
  • Founder & CEO: ALESSANDRO TOZZI
  • Web: endostart.com
  • Linkedin: Endostart S.r.l.
  • Eureka! Partner: ANNA AMATI

ENDOSTART

Endostart is a Florence-based MedTech start-up founded in 2018 by Alessandro Tozzi and based on key findings of his longstanding clinical work in gastroenterology.

Endostart has developed the Endorail System, a medical device that facilitates the fast completion of colonoscopies, through the use of a novel magnetic balloon technology. The Endorail System can be used during standard colonoscopies to prevent or resolve loop forming, which is a strong indicator for lengthy and incomplete colonoscopies. It is estimated that around 15% of world-wide colonoscopies (up to 50 M procedures annually) are incomplete or lengthy, resulting in lengthier time-to-diagnosis, the need of a second procedure, higher patient discomfort and higher costs for national health systems.

The Endorail System is composed of a standard endoscopic cannula with a balloon end, that is filled with a ferrofluid and anchored to the colon walls with an external permanent magnet. The simplicity of this solution, compatibility with current endoscopic tools and its ease of use, make the Endorail System a key tool of what will be the future best-in-class standard of colonoscopy.

EUREKA! VIEW

Endostart’s unique technological proposition, the Endorail System, combines simplicity, ease of use and compatibility with current endoscopic approaches. It has been developed by top class clinical experts, and shows strong patient and healthcare economics. The uniqueness of its USP is furthered also by the fact that novel magnetic materials in the Endorail System are currently being co-developed with top Italian scientists in the field of ferrofluids. The set of co-investors in this deal is top class in the MedTech field and our participation brings a further focus on materials innovation.